Skip to Main Content

Advertisement intended for health care professionals

Close

ASH Clinical News
ASH News Daily
ASH-SAP
Blood Journals
Hematology
The Hematologist
International
ASH
- ASH Home
- Research
- Education
- Advocacy
- Meetings
- Publications
- ASH Store

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current Issue
- All Issues
First edition
Abstracts
Collections
Author Center
About

Skip Nav Destination

Issue Archive

Select Decade

Select Year

Issue

Volume 130, Issue 5

August 3 2017

In this Issue

INSIDE BLOOD COMMENTARIES
PLENARY PAPER
PERSPECTIVE
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
GENE THERAPY
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
LETTERS TO BLOOD
BLOOD WORK

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY

Platelet-derived nanomedicine targets cancer

Eric Boilard

View Articletitled, Platelet-derived nanomedicine targets cancer

INSIDE BLOOD COMMENTARY

Targeted therapy of CNS leukemia?

Shai Izraeli,Cornelia Eckert

View Articletitled, Targeted therapy of CNS leukemia?

INSIDE BLOOD COMMENTARY

Zebrafish factor 10 and the life aquatic

John P. Sheehan

View Articletitled, Zebrafish factor 10 and the life aquatic

INSIDE BLOOD COMMENTARY

Sometimes less might be more, or at least equal

Michael Uhlin

View Articletitled, Sometimes less might be more, or at least equal

PLENARY PAPER

PLATELETS AND THROMBOPOIESIS

Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth

James V. Michael,Jeremy G. T. Wurtzel,Guang Fen Mao,A. Koneti Rao,Mikhail A. Kolpakov,Abdelkarim Sabri,Nicholas E. Hoffman,Sudarsan Rajan,Dhanendra Tomar,Muniswamy Madesh,Marvin T. Nieman,Johnny Yu,Leonard C. Edelstein,Jesse W. Rowley,Andrew S. Weyrich,Lawrence E. Goldfinger

View Articletitled, Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth

Supplemental data

PERSPECTIVE

Obinutuzumab: what is there to learn from clinical trials?

Guillaume Cartron,Hervé Watier

View Articletitled, Obinutuzumab: what is there to learn from clinical trials?

HOW I TREAT

How I treat double-hit lymphoma
Clinical Trials & Observations

Jonathan W. Friedberg

View Articletitled, How I treat double-hit lymphoma

CLINICAL TRIALS AND OBSERVATIONS

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Clinical Trials & Observations

Vaishali Sanchorawala,Giovanni Palladini,Vishal Kukreti,Jeffrey A. Zonder,Adam D. Cohen,David C. Seldin,Angela Dispenzieri,Arnaud Jaccard,Stefan O. Schönland,Deborah Berg,Huyuan Yang,Neeraj Gupta,Ai-Min Hui,Raymond L. Comenzo,Giampaolo Merlini

View Articletitled, A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

GENE THERAPY

NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease

Sara Mastaglio,Pietro Genovese,Zulma Magnani,Eliana Ruggiero,Elisa Landoni,Barbara Camisa,Giulia Schiroli,Elena Provasi,Angelo Lombardo,Andreas Reik,Nicoletta Cieri,Martina Rocchi,Giacomo Oliveira,Giulia Escobar,Monica Casucci,Bernhard Gentner,Antonello Spinelli,Anna Mondino,Attilio Bondanza,Luca Vago,Maurilio Ponzoni,Fabio Ciceri,Michael C. Holmes,Luigi Naldini,Chiara Bonini

View Articletitled, NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease

Supplemental data

HEMATOPOIESIS AND STEM CELLS

ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells
Brief Report

Brian S. Garrison,Adrian P. Rybak,Isabel Beerman,Balthasar Heesters,Francois E. Mercier,David T. Scadden,David Bryder,Roland Baron,Derrick J. Rossi

View Articletitled, ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells

Supplemental data

LYMPHOID NEOPLASIA

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome

Paolo Milani,Marco Basset,Francesca Russo,Andrea Foli,Giampaolo Merlini,Giovanni Palladini

View Articletitled, Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome

Supplemental data

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Tobias Dittrich,Tilmann Bochtler,Christoph Kimmich,Natalia Becker,Anna Jauch,Hartmut Goldschmidt,Anthony D. Ho,Ute Hegenbart,Stefan O. Schönland

View Articletitled, AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Supplemental data

Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor

Vera Münch,Luca Trentin,Julia Herzig,Salih Demir,Felix Seyfried,Johann M. Kraus,Hans A. Kestler,Rolf Köhler,Thomas F. E. Barth,Geertruy te Kronnie,Klaus-Michael Debatin,Lüder H. Meyer

View Articletitled, Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor

Supplemental data

MYELOID NEOPLASIA

Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine

Giulia Cheloni,Michele Tanturli,Ignazia Tusa,Ngoc Ho DeSouza,Yi Shan,Antonella Gozzini,Fréderic Mazurier,Elisabetta Rovida,Shaoguang Li,Persio Dello Sbarba

View Articletitled, Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine

Supplemental data

THROMBOSIS AND HEMOSTASIS

Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway

Zhilian Hu,Yang Liu,Michael C. Huarng,Marzia Menegatti,Deepak Reyon,Megan S. Rost,Zachary G. Norris,Catherine E. Richter,Alexandra N. Stapleton,Neil C. Chi,Flora Peyvandi,J. Keith Joung,Jordan A. Shavit

View Articletitled, Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway

Supplemental data

TRANSPLANTATION

Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion

Franco Locatelli,Pietro Merli,Daria Pagliara,Giuseppina Li Pira,Michela Falco,Daniela Pende,Roberto Rondelli,Barbarella Lucarelli,Letizia Pomponia Brescia,Riccardo Masetti,Giuseppe Maria Milano,Valentina Bertaina,Mattia Algeri,Rita Maria Pinto,Luisa Strocchio,Raffaella Meazza,Lavinia Grapulin,Rupert Handgretinger,Alessandro Moretta,Alice Bertaina,Lorenzo Moretta

View Articletitled, Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion

Supplemental data

LETTERS TO BLOOD

Genome-wide association study to identify variants associated with acute severe vaso-occlusive pain in sickle cell anemia

Shruti Chaturvedi,Pallav Bhatnagar,Christopher J. Bean,Martin H. Steinberg,Jaqueline N. Milton,James F. Casella,Emily Barron-Casella,Dan E. Arking,Michael R. DeBaun

View Articletitled, Genome-wide association study to identify variants associated with acute severe vaso-occlusive pain in sickle cell anemia

Supplemental data

Failure to replicate thrombomodulin genetic variant predictors of venous thromboembolism in African Americans

Aaron R. Folsom,Nicholas S. Roetker,Spencer T. Kelley,Weihong Tang,Nathan Pankratz

View Articletitled, Failure to replicate thrombomodulin genetic variant predictors of venous thromboembolism in African Americans

BLOOD WORK

Broken heart by T-prolymphocytic leukemia

Christian Arranto,Alexandar Tzankov

View Articletitled, Broken heart by T-prolymphocytic leukemia

Peripheral blood and bone marrow involvement by visceral leishmaniasis

Parker W. Clement,K. David Li

View Articletitled, Peripheral blood and bone marrow involvement by visceral leishmaniasis

Cover Image

Cover Image

Platelet-derived microparticles (shown in green) infiltrating solid tumors, including a grade 3-4 colon adenocarcinoma, suppress primary tumor growth by transferring platelet-derived microRNAs to tumor cells. See the article by Michael et al on page 567.
Front Matter
Table of Contents
Back Matter
Editorial Board

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia

Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads

Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

Leukemic myeloblasts with erythrophagocytosis

Advertisement intended for health care professionals

Advertisement intended for health care professionals

Current Issue
First edition
All Issues
Collections
Abstracts
Authors
Submit to Blood
About Blood
Subscriptions
Public Access
Permissions
Alerts
Contact Us
Newsroom
Blood Classifieds
Advertising in Blood
Terms and Conditions
Twitter

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Blood Global Hematology
Blood Neoplasia
Blood Vessels, Thrombosis & Hemostasis
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
Research
Education
Advocacy
Meetings
Publications
ASH Store

Copyright 2024 by American Society of Hematology

Cookie Settings
Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account

Advertisement intended for health care professionals